On April 13, 2016 CTI BioPharma Corp. (CTI) (NASDAQ and MTA:CTIC) reported that data highlighting pacritinib, pixantrone and tosedostat will be presented at the upcoming American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting to be held April 16-20 in New Orleans, LA (Press release, CTI BioPharma, APR 12, 2016, View Source;p=RssLanding&cat=news&id=2156655 [SID:1234510734]). The abstracts are available on the AACR (Free AACR Whitepaper) website at www.aacr.org.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Poster Presentations
Pacritinib
Combinatorial strategies for glioblastoma using brain tumor-initiating cells: targeting the JAK/STAT and EGFR pathways
First Author: Hema Luchman, Ph.D., Hotchkiss Brain Institute, University of Calgary, Calgary, AB
Date/Time: Sunday, April 17 at 1:00 p.m.-5:00 p.m. ET
Location: Section 15
Poster Session: Combinatorial Strategies
Abstract #279 / Poster Board #20
The nonclinical toxicology profile of pacritinib, a JAK2/FLT3 inhibitor with no dose-limiting clinical myelosuppression
First Author: Rebecca Watson, CTI BioPharma Corp., Seattle, WA
Date/Time: Monday, April 18 at 1:00 p.m.-5:00 p.m. ET
Location: Section 37
Poster Session: Targets, Markers, and Agents in Cancer Prevention
Abstract #2602 / Poster Board #2
Pacritinib reduces human myeloid leukemia stem cell maintenance in a defined niche
First Author: Larissa Balaian, Ph.D., Moores Cancer Center, University of California, San Diego, CA
Date/Time: Tuesday, April 19 at 8:00 a.m.-12:00 p.m. ET
Location: Section 32
Poster Session: Stemness Properties of Leukemias and Carcinomas
Abstract #3338 / Poster Board #6
Investigation of absorption, metabolism, excretion, and mass balance of [14C]-pacritinib in healthy subjects: a phase 1 study
First Author: Suliman Al-Fayoumi, CTI BioPharma Corp., Seattle, WA
Date/Time: Wednesday, April 20 at 8:00 a.m.-12:00 p.m. ET
Location: Section 13
Poster Session: Phase 1 Clinical Trials 2
Abstract #CT159 / Poster Board #20
Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal growth factor receptor mutation-positive non-small cell lung cancer
First Author: Nobuaki Ochi, M.D., Ph.D., Kawasaki Medical School, Okayama, Japan
Date/Time: Wednesday, April 20 at 8:00 a.m.-12:00 p.m. ET
Location: Section 15
Poster Session: Combination Therapies and Approaches to Sensitizing Cancer Cells to Drugs
Abstract #4675 / Poster Board #16
Pixantrone
Combinations containing the aza-anthracenedione pixantrone show preclinical activity in diffuse large B-cell lymphoma (DLBCL)
First Author: Chiara Tarantelli, Ph.D., IOR Institute of Oncology Research, Bellinzona, Switzerland
Date/Time: Wednesday, April 20 at 8:00 a.m.-12:00 p.m. ET
Location: Section 19
Poster Session: Novel Chemotherapies
Abstract #4793 / Poster Board #18
Tosedostat
Enhancing the efficacy of tosedostat through carboxylesterase induction
First Author: Priscilla Wei Ling Hong, Ph.D., The University of Queensland Diamantina Institute, Brisbane, Australia
Date/Time: Wednesday, April 20 at 8:00 a.m.-12:00 p.m. ET
Location: Section 20
Poster Session: Targeted Therapy
Abstract #4806 / Poster Board #1
About Pacritinib
Pacritinib is an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R. In August 2014, pacritinib was granted Fast Track designation by the FDA for the treatment of intermediate and high risk myelofibrosis including, but not limited to, patients with disease-related thrombocytopenia (low platelet counts); patients experiencing treatment-emergent thrombocytopenia on other JAK2 inhibitor therapy; or patients who are intolerant of, or whose symptoms are not well controlled (sub-optimally managed) on other JAK2 therapy. Clinical studies for pacritinib are currently subject to a full clinical hold issued by the U.S. Food and Drug Administration in February 2016.
CTI BioPharma and Baxalta Incorporated are parties to a worldwide license agreement to develop and commercialize pacritinib. CTI BioPharma and Baxalta will jointly commercialize pacritinib in the U.S. while Baxalta has exclusive commercialization rights for all indications outside the U.S.
About PIXUVRI (pixantrone)
PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. PIXUVRI was structurally designed so that it cannot bind iron and perpetuate oxygen radical production or form a long-lived hydroxyl metabolite — both of which are the putative mechanisms for anthracycline induced acute and chronic cardiotoxicity.
In May 2012, the European Commission granted conditional marketing authorization for PIXUVRI as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive NHL. The benefit of PIXUVRI treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy. The Summary of Product Characteristics (SmPC) has the full prescribing information, including the safety and efficacy profile of PIXUVRI in the approved indication. The SmPC is available at www.pixuvri.eu. PIXUVRI does not have marketing approval in the United States.
About Tosedostat
Tosedostat is an investigational oral aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood-related cancers and solid tumors in Phase 1-2 clinical trials. Tosedostat is currently being evaluated in multiple Phase 2 clinical trials for the treatment of patients with AML or high-risk MDS. Tosedostat is not approved or commercially available.